An Early Phase 1 interventional study of Dual GLP-1/GLP-2 Receptor agonists in Healthy, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-02.
Sponsored by Zealand Pharma · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, placebo-controlled, single ascending dose trial in healthy subjects, randomized to ZP7570 or placebo within each cohort.
Sixty-four subjects are planned to be studied in eight cohorts in this first-in human trial. Eight subjects will be allocated to the to eight dose levels. The entire observation period comprise 28 days starting with a 96 hours in-house stay, where discharge is planned for Day 5, followed by five outpatient visits and an End of Trial Visit at Day 28. A blinded evaluation of each cohort will be performed by a Trial Safety Group to determine whether the trial will progress to the next dose level based on the stopping rules specified in protocol.
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single subcutaneous injection
Drug: Dual GLP-1/GLP-2 Receptor agonists
Single subcutaneous injection
Drug: Dual GLP-1/GLP-2 Receptor agonists
Drug page: Dapiglutide
Eight ascending doses of ZP7570
Also known as: ZP7570
Safety - Incidence of adverse events (AEs)
The incidence, type and severity of adverse events (AEs)
Time frame: From time zero to 28 days after dosing
Pharmacokinetics - Area under the plasma concentration-time curve trough
AUCτ, Area under the plasma concentration-time curve (AUC) from zero up to trough concentration.
Time frame: From time zero up to day 28
Pharmacokinetics - Area under the plasma concentration-time curve infinity
AUCinf, Area under the plasma concentration-time curve (AUC) from zero up to last concentration.
Time frame: From time zero up to day 28
Pharmacokinetics - Area under the plasma concentration-time curve last
AUClast, Area under the plasma concentration-time curve (AUC) from zero up to last concentration
Time frame: From time zero up to day 28
Pharmacokinetics - Maximum plasma concentration
Measured maximum plasma drug concentration after dosing, Cmax
Time frame: From time zero to 28 days after dosing
Pharmacokinetics - Time to maximum plasma concentration (Tmax)
Sampling time until reaching Cmax, Tmax
Time frame: From time zero to 28 days after dosing
Pharmacokinetics - Half-life , t½
Half-life of ZP7570, t½
Time frame: From time zero to 28 days after dosing
Pharmacokinetics - Volume of distribution
Apparent volume of distribution of ZP7570, Vz/f
Time frame: From time zero to 28 days after dosing
Pharmacokinetics - Mean residence time
Mean residence time, MRT
Time frame: From time zero to 28 days after dosing
Pharmacokinetics - Body clearance
Total body clearance, CL/f
Time frame: From time zero to 28 days after dosing
Pharmacokinetics - Elimination rate constant
Elimination rate constant, λz
Time frame: From time zero to 28 days after dosing
Pharmacodynamics - Plasma glucose levels
Plasma glucose levels included with the acetaminophen at specific timepoints relative to a Mixed Test Meal
Time frame: Time Frame: 0-240 minutes
Pharmacodynamics - Insulin concentrations
Insulin concentrations included with the acetaminophen at specific timepoints relative to a Mixed Test Meal
Time frame: Time Frame: 0-240 minutes
Pharmacodynamics - Plasma acetaminophen concentration-time curves
Plasma acetaminophen concentration-time curves following ingestion of acetaminophen
Time frame: Time Frame: 0-240 minutes
Pharmacodynamics - Maximum acetaminophen concentration
Change from baseline acetaminophen to maximum acetaminophen
Time frame: Time Frame: 0-240 minutes
Pharmacodynamics - Time maximum acetaminophen concentration
Time to maximum change in acetaminophen measure from baseline, Tmax
Time frame: Time Frame: 0-240 minutes
Safety - Safety lab, haematology
Changes in haematology parameters: Haematocrit, Haemoglobin, Erythrocytes, MCV, MCH, MCHC, platelets, Leucocytes, Neutrophile granulocytes (total count and relative), Lymphocytes (total count and relative), Monocytes (total count and relative), Eosinophile granulocytes (total count and relative), Basophile granulocytes (total count and relative)
Time frame: From time zero to 28 days after dosing
Safety - Safety lab, clinical chemistry
Changes in clinical chemistry parameters: Sodium, Potassium, Calcium, Creatinine, Urea, AST, ALT, gamma-GT, Uric acid, Total protein, Albumin, Total bilirubin, Creatine kinase, Alkaline phosphatase, LDH, Total cholesterol, LDL, HDL, Amylase, Triglycerides, Lipase
Time frame: From time zero to 28 days after dosing
Safety - Safety lab, urinalysis
Changes in urinalysis: Protein, Glucose Erythrocytes, Leucocytes, pH, ketones
Time frame: From time zero to 28 days after dosing
Safety - Vital signs, blood pressure
Changes in vital signs, blood pressure (in mmHG)
Time frame: From time zero to 28 days after dosing
Safety - Vital signs, pulse
Changes in pulse (beats per minute)
Time frame: From time zero to 28 days after dosing
Safety - Physical examination
Changes in physical examination of body sections (head, chest and heart, abdomen, skin and mucosae, musculoskeletal system, nervous system, lymph node)
Time frame: From time zero to 28 days after dosing
Safety - ECG
Occurrence of ECG findings, Changes in ECG parameters (in ms). ECG components: Heart rate, PR, QRS, QT and QTcF.
Time frame: From time zero to 28 days after dosing
Safety - Occurrence of Injection site reactions
Occurrence of injection site reactions
Time frame: From time zero to 28 days after dosing
Safety - Immunogenicity: Occurrence of anti-drug antibodies
Occurrence of anti-drug antibodies
Time frame: From time zero to 28 days after dosing
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2019 to primary completion in Nov 2020, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapiglutide